PHARMACEUTICAL wholesaler, EBOS, has reported a 25% increase in revenue for the first half of the 2020 Financial Year, to $4.4 billion, fuelled by growth from its community pharmacy business.
The group, which includes Community Service Obligation wholesaler, Symbion, saw a 35.4% increase in revenue from its pharmacy business, following the commencement of its Chemist Warehouse Group (CWH) pharmaceutical wholesale contract, and the expansion of its TerryWhite Chemmart Group (TWC), EBOS CEO, John Cullity said.
"The growth in our pharmacy wholesale and contract logistics business is testament to the Group's capital investment strategy over recent years, which has enabled us to productively manage the significant uplift in volumes and revenues," he said.
Cullity noted that 16 new TWC pharmacies opened in the first half of FY20, with the network reporting sales growth of 5.7%, while prescription sales, on a like-for-like basis grew 5.3%, driven by increased brand awareness, customer satisfaction and new programs including ties with Qantas Frequent Flyers, Bupa and Afterpay.
In its H1FY20 results EBOS posted a statutory net profit after tax of $81.7 million, up 21.8% on the previous corresponding period, while earnings before interest, tax, depreciation and amortisation jumped 36.4% on the H1FY19 results
The company declared an interim dividend of NZ$0.375 cents per share, an 8.7% increase on prior corresponding period, with the fully franked dividend to be paid on 03 Apr.
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Feb 20
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Feb 20
